New immunotherapy shows promise against multiple advanced cancers
NCT ID NCT02908906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts: first to find the safest dose, then to see how well it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cetrelimab (JNJ-63723283), an immunotherapy drug that helps the immune system attack cancer cells
What this could lead to
If successful, this could provide a new treatment option for several advanced cancers, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so the drug may not work for many people. Immunotherapy can cause serious side effects like inflammation in healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
St Louis, Missouri, United States
-
Study site
Pittsburgh, Pennsylvania, United States
-
Study site
Chisinau, Moldova
-
Study site
Bialystok, Poland
-
Study site
Warsaw, Poland
-
Study site
Moscow, Russia
-
Study site
Pyatigorsk, Russia
-
Study site
Saint Petersburg, Russia
-
Study site
Badalona, Spain
-
Study site
Barcelona, Spain
-
Study site
Madrid, Spain
-
Study site
Málaga, Spain
-
Study site
Pamplona, Spain
-
Study site
Seville, Spain
-
Study site
Valencia, Spain
-
Study site
Gothenburg, Sweden
-
Study site
Glasgow, United Kingdom
-
Study site
London, United Kingdom
-
Study site
Manchester, United Kingdom
-
Study site
Newcastle upon Tyne, United Kingdom